vs
CSG SYSTEMS INTERNATIONAL INC（CSGS）とPHIBRO ANIMAL HEALTH CORP（PAHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
PHIBRO ANIMAL HEALTH CORPの直近四半期売上が大きい（$373.9M vs $323.1M、CSG SYSTEMS INTERNATIONAL INCの約1.2倍）。PHIBRO ANIMAL HEALTH CORPの純利益率が高く（7.3% vs 2.2%、差は5.2%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs 2.0%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $8.3M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 4.6%）
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
CSGS vs PAHC — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $323.1M | $373.9M |
| 純利益 | $7.0M | $27.5M |
| 粗利率 | 50.0% | 35.5% |
| 営業利益率 | 9.0% | 13.5% |
| 純利益率 | 2.2% | 7.3% |
| 売上前年比 | 2.0% | 20.9% |
| 純利益前年比 | -79.7% | 762.1% |
| EPS（希薄化後） | $0.24 | $0.67 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $323.1M | $373.9M | ||
| Q3 25 | $303.6M | $363.9M | ||
| Q2 25 | $297.1M | $378.7M | ||
| Q1 25 | $299.5M | $347.8M | ||
| Q4 24 | $316.7M | $309.3M | ||
| Q3 24 | $295.1M | $260.4M | ||
| Q2 24 | $290.3M | $273.2M | ||
| Q1 24 | $295.1M | $263.2M |
| Q4 25 | $7.0M | $27.5M | ||
| Q3 25 | $20.5M | $26.5M | ||
| Q2 25 | $12.3M | $17.2M | ||
| Q1 25 | $16.1M | $20.9M | ||
| Q4 24 | $34.5M | $3.2M | ||
| Q3 24 | $19.1M | $7.0M | ||
| Q2 24 | $13.8M | $752.0K | ||
| Q1 24 | $19.5M | $8.4M |
| Q4 25 | 50.0% | 35.5% | ||
| Q3 25 | 48.1% | 32.9% | ||
| Q2 25 | 49.5% | 29.0% | ||
| Q1 25 | 48.4% | 30.1% | ||
| Q4 24 | 51.3% | 32.9% | ||
| Q3 24 | 49.4% | 32.1% | ||
| Q2 24 | 47.3% | 31.9% | ||
| Q1 24 | 46.5% | 30.2% |
| Q4 25 | 9.0% | 13.5% | ||
| Q3 25 | 10.0% | 14.1% | ||
| Q2 25 | 10.0% | 8.9% | ||
| Q1 25 | 9.8% | 9.6% | ||
| Q4 24 | 13.4% | 8.3% | ||
| Q3 24 | 10.8% | 6.8% | ||
| Q2 24 | 8.8% | 6.7% | ||
| Q1 24 | 10.8% | 7.6% |
| Q4 25 | 2.2% | 7.3% | ||
| Q3 25 | 6.7% | 7.3% | ||
| Q2 25 | 4.1% | 4.5% | ||
| Q1 25 | 5.4% | 6.0% | ||
| Q4 24 | 10.9% | 1.0% | ||
| Q3 24 | 6.5% | 2.7% | ||
| Q2 24 | 4.8% | 0.3% | ||
| Q1 24 | 6.6% | 3.2% |
| Q4 25 | $0.24 | $0.67 | ||
| Q3 25 | $0.73 | $0.65 | ||
| Q2 25 | $0.44 | $0.43 | ||
| Q1 25 | $0.57 | $0.51 | ||
| Q4 24 | $1.20 | $0.08 | ||
| Q3 24 | $0.67 | $0.17 | ||
| Q2 24 | $0.48 | $0.02 | ||
| Q1 24 | $0.68 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.0M | $74.5M |
| 総負債低いほど良い | $539.5M | $624.2M |
| 株主資本純資産 | $283.7M | $332.4M |
| 総資産 | $1.5B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 1.90× | 1.88× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.0M | $74.5M | ||
| Q3 25 | $158.4M | $85.3M | ||
| Q2 25 | $145.9M | $77.0M | ||
| Q1 25 | $136.0M | $70.4M | ||
| Q4 24 | $161.8M | $67.1M | ||
| Q3 24 | $118.4M | $89.8M | ||
| Q2 24 | $110.4M | $114.6M | ||
| Q1 24 | $120.8M | $98.7M |
| Q4 25 | $539.5M | $624.2M | ||
| Q3 25 | $538.6M | $628.0M | ||
| Q2 25 | $537.8M | $631.7M | ||
| Q1 25 | $537.6M | $635.4M | ||
| Q4 24 | $538.5M | $639.1M | ||
| Q3 24 | $539.5M | $295.2M | ||
| Q2 24 | $540.5M | $312.1M | ||
| Q1 24 | $541.5M | — |
| Q4 25 | $283.7M | $332.4M | ||
| Q3 25 | $289.5M | $311.7M | ||
| Q2 25 | $290.7M | $285.7M | ||
| Q1 25 | $283.1M | $266.0M | ||
| Q4 24 | $282.6M | $246.8M | ||
| Q3 24 | $288.4M | $258.5M | ||
| Q2 24 | $273.3M | $256.6M | ||
| Q1 24 | $269.3M | $270.1M |
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.4B | $966.3M | ||
| Q2 24 | $1.4B | $982.2M | ||
| Q1 24 | $1.3B | $979.0M |
| Q4 25 | 1.90× | 1.88× | ||
| Q3 25 | 1.86× | 2.01× | ||
| Q2 25 | 1.85× | 2.21× | ||
| Q1 25 | 1.90× | 2.39× | ||
| Q4 24 | 1.91× | 2.59× | ||
| Q3 24 | 1.87× | 1.14× | ||
| Q2 24 | 1.98× | 1.22× | ||
| Q1 24 | 2.01× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.2M | $19.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $55.8M | $8.3M |
| FCFマージンFCF / 売上 | 17.3% | 2.2% |
| 設備投資強度設備投資 / 売上 | 1.1% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | 8.46× | 0.70× |
| 直近12ヶ月FCF直近4四半期 | $141.4M | $47.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $59.2M | $19.4M | ||
| Q3 25 | $47.9M | $9.3M | ||
| Q2 25 | $37.3M | $21.3M | ||
| Q1 25 | $11.5M | $43.2M | ||
| Q4 24 | $82.5M | $3.1M | ||
| Q3 24 | $39.5M | $12.6M | ||
| Q2 24 | $43.1M | $28.4M | ||
| Q1 24 | $-29.4M | $11.4M |
| Q4 25 | $55.8M | $8.3M | ||
| Q3 25 | $43.9M | $-4.5M | ||
| Q2 25 | $34.6M | $8.1M | ||
| Q1 25 | $7.1M | $35.4M | ||
| Q4 24 | $76.6M | $-4.7M | ||
| Q3 24 | $32.0M | $3.0M | ||
| Q2 24 | $38.8M | $15.4M | ||
| Q1 24 | $-34.1M | $1.7M |
| Q4 25 | 17.3% | 2.2% | ||
| Q3 25 | 14.5% | -1.2% | ||
| Q2 25 | 11.6% | 2.1% | ||
| Q1 25 | 2.4% | 10.2% | ||
| Q4 24 | 24.2% | -1.5% | ||
| Q3 24 | 10.8% | 1.2% | ||
| Q2 24 | 13.4% | 5.6% | ||
| Q1 24 | -11.6% | 0.6% |
| Q4 25 | 1.1% | 3.0% | ||
| Q3 25 | 1.3% | 3.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 1.5% | 2.2% | ||
| Q4 24 | 1.9% | 2.5% | ||
| Q3 24 | 2.5% | 3.7% | ||
| Q2 24 | 1.5% | 4.8% | ||
| Q1 24 | 1.6% | 3.7% |
| Q4 25 | 8.46× | 0.70× | ||
| Q3 25 | 2.34× | 0.35× | ||
| Q2 25 | 3.04× | 1.24× | ||
| Q1 25 | 0.71× | 2.07× | ||
| Q4 24 | 2.39× | 0.97× | ||
| Q3 24 | 2.07× | 1.81× | ||
| Q2 24 | 3.12× | 37.80× | ||
| Q1 24 | -1.51× | 1.36× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
